PD-1 expression on peripheral blood CD4+ T lymphocytes in treatment-naïve HNSCC patients: a flow cytometry analysis
DOI:
https://doi.org/10.18203/2320-6012.ijrms20252412Keywords:
CD4 lymphocytes, Flow cytometry, Head and neck squamous cell carcinoma , Immune checkpoint, Metastasis, Programmed death protein-1Abstract
Background: Head and neck squamous cell carcinoma (HNSCC) is a globally prevalent malignancy with a high burden in India. Programmed death protein-1 (PD-1), an immune checkpoint receptor, is a potential biomarker in several cancers. However, its prognostic relevance on circulating CD4+ T cells in HNSCC remains uncertain. To evaluate PD-1 expression on peripheral blood CD4+ T lymphocytes in treatment-naïve HNSCC patients and determine its association with clinicopathological features.
Methods: This prospective, cross-sectional study included 32 histopathologically confirmed, treatment-naïve HNSCC patients at a tertiary care center over 18 months. Peripheral blood mononuclear cells were analyzed using flow cytometry (Cytomics FC 500, Beckman Coulter) with antibodies against CD3, CD4 and PD-1 (CD279). PD-1 expression was quantified on gated CD4+ T cells. Statistical analysis was performed using SPSS v25.0, with significance set at p<0.05.
Results: The mean age was 49.94±10.5 years; all patients were male. The most common tumor sites were palate (40.63%), tongue (31.25%) and oral mucosa (28.13%). The mean PD-1 expression on CD4+ T lymphocytes was 5.51±2.06%. PD-1 expression showed no statistically significant association with tumor site (p=0.843), histological differentiation (p=0.363), lymph node metastasis (p=0.930) or tumor stage (p=0.930).
Conclusions: PD-1 expression on peripheral CD4+ T cells does not correlate with tumor site, grade, stage or metastatic status in HNSCC patients. While flow cytometric quantification of PD-1 may offer non-invasive insights, its standalone utility as a prognostic marker in peripheral blood appears limited. Larger studies incorporating tumor microenvironment analysis and longitudinal follow-up are warranted.
Metrics
References
Jemal A, Bray F, Ferlay J, Ward E, Forman D, Center MM. Global cancer statistics. CA Cancer J Clin 2011;61(2):69–90. DOI: https://doi.org/10.3322/caac.20107
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):359–86. DOI: https://doi.org/10.1002/ijc.29210
Joshi P, Dutta S, Chaturvedi P, Nair S. Head and neck cancers in developing countries. Rambam Maimonides Med J 2014;5(2):9. DOI: https://doi.org/10.5041/RMMJ.10143
Kulkarni MR. Head and neck cancer burden in India. Int J Head Neck Surg. 2013;4(1):29- 35. DOI: https://doi.org/10.5005/jp-journals-10001-1132
Waki K, Yamada T, Yoshiyama K, Terazaki Y, Sakamoto S, Matsueda S, et al. PD-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancer. Cancer Sci 2014;105(10):1229–35. DOI: https://doi.org/10.1111/cas.12502
Wu XL, Tu Q, Faure G, Gallet P, Kohler C, Bittencourt MD, et al. Diagnostic and Prognostic Value of Circulating Tumor Cells in Head and Neck Squamous Cell Carcinoma: A systematic review and meta-analysis. Sci Rep. 2016;6:20210. DOI: https://doi.org/10.1038/srep20210
Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10(3):727-42.
Zanoni DK, Patel SG, Shah JP. Changes in the 8th Edition of the American Joint Committee on Cancer (AJCC) Staging of Head and Neck Cancer: Rationale and Implications. Curr Oncol Rep. 2019;21(6):52. DOI: https://doi.org/10.1007/s11912-019-0799-x
Chang PH, Wu MH, Liu SY, Wang HM, Huang WK, Liao CT, et al. The prognostic roles of pretreatment circulating tumor cells, circulating cancer stem-like cells and programmed cell death-1 expression on peripheral lymphocytes in patients with initially unresectable, recurrent or metastatic head and neck cancer: an exploratory study of three biomarkers in one-time blood drawing. Cancers. 2019;15;11(4):540. DOI: https://doi.org/10.3390/cancers11040540
Yavrouian EJ, Sinha UK. Recent advances in biomarkers and potential targeted therapies in head and neck squamous cell carcinoma. ISRN Surg 2012;20:715743. DOI: https://doi.org/10.5402/2012/715743
Yang WF, Wong MCM, Thomson PJ, Li KY, Su YX. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis. Oral Oncol. 2018;86:81-90. DOI: https://doi.org/10.1016/j.oraloncology.2018.09.016
Lin YM, Sung WW, Hsieh MJ, Tsai SC, Lai HW, Yang SM, et al. High PD-L1 expression correlates with metastasis and poor prognosis in oral squamous cell carcinoma. PLoS ONE. 2015;10:142656. DOI: https://doi.org/10.1371/journal.pone.0142656
Gilyoma JM, Rambau PF, Masalu N, Kayange NM, Chalya PL. Head and neck cancers: a clinico-pathological profile and management challenges in a resource-limited setting. BMC Res Notes. 2015;8:772. DOI: https://doi.org/10.1186/s13104-015-1773-9
Liu SA, Wang CC, Jiang RS, Lee FY, Lin WJ, Lin JC. Pathological features and their prognostic impacts on oral cavity cancer patients among different subsites – A singe institute’s experience in Taiwan. Sci Rep. 2017;7:7451. DOI: https://doi.org/10.1038/s41598-017-08022-w
Basumatari S, Datta B, Deka AJ. Demographic and epidemiological profile in ent and head and neck cancer patients. J Evol Med Dent Sci. 2017;6:6417–22. DOI: https://doi.org/10.14260/jemds/2017/1396
Bouckaert, Munzhelele T, Feller L, Lemmer J, Rag K. The clinical characteristics of oral squamous cell carcinoma in patients attending the Medunsa Oral Health Centre, South Africa Integr Cancer Sci Therap. 2016;3(5):575-8.
Fasunla AJ, Ogundoyin OA, Onakoya PA, Nwaorgu OG. Malignant tumors of the larynx: Clinicopathologic profile and implication for late disease presentation. Niger Med J Niger Med Assoc. 2016;57:280–5. DOI: https://doi.org/10.4103/0300-1652.190596
Sidhu A, Dhaliwal SS, Singh S. Clinical profile of patients of head and neck cancers- a prospective study of 100 cases. Int J Curr Adv Res. 2020;9(3):21472-8.
Carpén T, Sjöblom A, Lundberg M, Haglund C, Markkola A, Syrjänen S, et al. Presenting symptoms and clinical findings in HPV-positive and HPV-negative oropharyngeal cancer patients. Acta Otolaryngol (Stockh). 2017;138:1–6. DOI: https://doi.org/10.1080/00016489.2017.1405279
McIlwain WR, Sood AJ, Nguyen SA, Day TA. Initial symptoms in patients with HPV- Positive and HPV-negative oropharyngeal cancer. JAMA Otolaryngol Neck Surg. 2014;140:441–7. DOI: https://doi.org/10.1001/jamaoto.2014.141
Molina JR, Aubry MC, Lewis JE, Wampfler JA, Williams BA, Midthun DE, et al. Primary salivary gland-type lung cancer: spectrum of clinical presentation, histopathologic and prognostic factors. Cancer. 2007;110:2253–9. DOI: https://doi.org/10.1002/cncr.23048
Alam MS, Siddiqui SA, Perween R. Epidemiological profile of head and neck cancer patients in Western Uttar Pradesh and analysis of distributions of risk factors in relation to site of tumor. J Cancer Res Ther. 2017;13:430–5.
Elrefaey S, Massaro MA, Chiocca S, Chiesa F, Ansarin M. HPV in oropharyngeal cancer: the basics to know in clinical practice. Acta Otorhinolaryngol Ital. 2014;34(5):299-309.
Rathore S, Rashmi MV, Singh PK. EGFR scoring in head and neck squamous cell carcinoma and its association with clinicopathological variables. Int J Med Res Review. 2017;5(7):731-9. DOI: https://doi.org/10.17511/ijmrr.2017.i07.12
Ibrahim D, Hasaballah M, El-Begermy M, Ahmed A, Abuelela S. Impact of pre- radiotherapy and/or chemoradiotherapy hemoglobin level on response to treatment in laryngeal and hypophayrngeal squamous cell carcinoma. J Cancer Therapy. 2018;9:362- 81. DOI: https://doi.org/10.4236/jct.2018.94033
Narayanaswamy RK, Potharaju M, Vaidhyswaran AN, Perumal K. Pre-radiotherapy haemoglobin level is a prognosticator in locally advanced head and neck cancers treated with concurrent chemoradiation. J Clin Diagn Res. 2015;9:14-8. DOI: https://doi.org/10.7860/JCDR/2015/11593.6102
Schafer U, Micke O, Muller SB, Schuller P, Willich N. Hemoglobin as an Independent Prognostic Factor in the Radiotherapy of Head and Neck Tumors. Strahlentherapie und Onkologie. 2003;179:527-34. DOI: https://doi.org/10.1007/s00066-003-1117-x
Montgomery J, Syed MI, Rana I, Singh J, Clark LJ. Hemoglobin monitoring in head and neck cancer patients undergoing radiotherapy. Annal Otol Rhinol Laryngol. 2010;119:472-5. DOI: https://doi.org/10.1177/000348941011900708
Haddad R, Suntharalingam M, Chen T. Pretreatment hemoglobin is associated with response to chemoradiation therapy (CRT) in patients with advanced unresectable squamous cell carcinoma of the head and neck. Proceed Am Soc Clin Oncol. 2001;19:417.
Hong AM, Vilain RE, Romanes S, Yang J, Smith E, Jones D, et al. PD-L1 expression in tonsillar cancer is associated with human papillomavirus positivity and improved survival: implications for anti-PD1 clinical trials. Oncotarget 2016;7(47):77010-20. DOI: https://doi.org/10.18632/oncotarget.12776
MacFarlane AW, Jillab M, Plimack ER, Hudes GR, Uzzo RG, Litwin S, et al. PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection. Cancer Immunol Res. 2014;2(4):320-31. DOI: https://doi.org/10.1158/2326-6066.CIR-13-0133
Buderath P, Schwich E, Jensen C, Horn PA, Kimmig R, Kasimir-Bauer S, et al. Soluble programmed death receptor ligands sPD-L1 and sPDL2 as liquid biopsy markers for prognosis and platinum response in epithelial ovarian cancer. Front Oncol. 2019;9:1015. DOI: https://doi.org/10.3389/fonc.2019.01015
Theodoraki MN, Yerneni SS, Hoffmann TK, Gooding WE, Whiteside TL. Clinical significance of PD-L1(+) exosomes in plasma of head and neck cancer patients. Clin Cancer Res. 2018;24:896–905. DOI: https://doi.org/10.1158/1078-0432.CCR-17-2664
Rodig N, Ryan T, Allen JA, Pang H, Grabie N, Chernova T, et al. Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis. Eur J Immunol. 2003;33:3117–26. DOI: https://doi.org/10.1002/eji.200324270
Tsushima F, Tanaka K, Otsuki N, Youngnak P, Iwai H, Omura K, et al. Predominant expression of B7-H1 and its immunoregulatory roles in oral squamous cell carcinoma. Oral Oncol. 2006;42:268–74. DOI: https://doi.org/10.1016/j.oraloncology.2005.07.013
Chen J, Feng Y, Lu L, Wang H, Dai L, Li Y, et al. Interferon-g-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway. Immunobiology 2012;217:385–93. DOI: https://doi.org/10.1016/j.imbio.2011.10.016
Qiao XW, Jiang J, Pang X, Huang MC, Tang YJ, Liang XH, et al. The evolving landscape of PD-1/PD-L1 pathway in head and neck cancer. Front Immunol. 2020;11:1721. DOI: https://doi.org/10.3389/fimmu.2020.01721
Lyford-Pike S, Peng S, Young GD, Taube JM, Westra WH, Akpeng B, et al. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res. 2013;73(6):1733-41. DOI: https://doi.org/10.1158/0008-5472.CAN-12-2384
Kim HS, Lee JY, Lim SH, Park K, Sun JM, Ko YH, et al. Association between PD-L1 and HPV status and the prognostic value of PD-L1 in oropharyngeal squamous cell carcinoma. Cancer Res Treat. 2016;48(2):527-36. DOI: https://doi.org/10.4143/crt.2015.249
Mattox AK, Lee J, Westra WH, Pierce RH, Ghossein R, Faquin WC, et al. PD-1 expression in head and neck squamous cell carcinomas derives primarily from functionally anergic CD4+ TILs in the presence of PD-L1+ TAMs. Cancer Res. 2017;77(22):6365-74. DOI: https://doi.org/10.1158/0008-5472.CAN-16-3453
Balermpas P, Rödel F, Krause M, Linge A, Lohaus F, Baumann M, et al. The PD-1/PD- L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: a multicentre study of the German cancer consortium radiation oncology group (DKTK-ROG). Int J Cancer. 2017;141:594–603. DOI: https://doi.org/10.1002/ijc.30770
Ou D, Adam J, Garberis I, Blanchard P, Nguyen F, Levy A, et al. Clinical relevance of tumor infiltrating lymphocytes, PD-L1 expression and correlation with HPV/p16 in head and neck cancer treated with bio- or chemo-radiotherapy. Oncoimmunology. 2017;6(9):1341030. DOI: https://doi.org/10.1080/2162402X.2017.1341030
Lee Y, Shin JH, Longmire M, Wang H, Kohrt HE, Chang HY, et al. CD44+ cells in head and neck squamous cell carcinoma suppress T-cell-mediated immunity by selective constitutive and inducible expression of PD-L1. Clin Cancer Res. 2016;22:3571–81. DOI: https://doi.org/10.1158/1078-0432.CCR-15-2665
Zhang W, Bai JF, Zuo MX, Cao XX, Chen M, Zhang Y, et al. PD-1 expression on the surface of peripheral blood CD4+ T cell and its association with the prognosis of patients with diffuse large B-cell lymphoma. Cancer Med. 2016;5(11):3077–84. DOI: https://doi.org/10.1002/cam4.874
Vassilakopoulou M, Avgeris M, Velcheti V, Kotoula V, Rampias T, Chatzopoulos K, et al. Evaluation of PD-L1 cinoma. Clin Cancer Res. 2016;22:704–13. DOI: https://doi.org/10.1158/1078-0432.CCR-15-1543
Lyu X, Zhang M, Li G, Jiang Y, Qiao Q. PD-1 and PD-L1 Expression Predicts Radiosensitivity and Clinical Outcomes in Head and Neck Cancer and is Associated with HPV Infection. J Cancer. 2019;10(4):937-48. DOI: https://doi.org/10.7150/jca.27199
Strati A, Koutsodontis G, Papaxoinis G, Angelidis I, Zavridou M, Economopoulou P, et al. Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma. Ann Oncol. 2017;28(8):1923-33. DOI: https://doi.org/10.1093/annonc/mdx206
Ibrahim R, Stewart R, Shalabi A. PD-L1 blockade for cancer treatment: MEDI4736. Semin Oncol. 2015;42:474–83. DOI: https://doi.org/10.1053/j.seminoncol.2015.02.007
Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G Jr, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394:1915–28. DOI: https://doi.org/10.1016/S0140-6736(19)32591-7
Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of checkMate 141 with analyses by tumor PD-L1 expression. Oral Oncol. 2018;81:45–51. DOI: https://doi.org/10.1016/j.oraloncology.2018.04.008
Moratin J, Metzger K, Safaltin A, Herpel E, Hoffmann J, Freier K, et al. Upregulation of PD-L1 and PD-L2 in neck node metastases of head and neck squamous cell carcinoma. Head Neck. 2019;41:2484–91. DOI: https://doi.org/10.1002/hed.25713
Vaidya P, Mehta A, Ragab O, Lin S, In GK. Concurrent radiation therapy with programmed cell death protein 1 inhibition leads to a complete response in advanced cutaneous squamous cell carcinoma. JAAD Case Rep. 2019;5(9):763-6. DOI: https://doi.org/10.1016/j.jdcr.2019.06.026
Shibata H, Saito S, Uppaluri R. Immunotherapy for head and neck cancer: a paradigm shift from induction chemotherapy to neoadjuvant immunotherapy. Front Oncol. 2021;11:727433. DOI: https://doi.org/10.3389/fonc.2021.727433
Downloads
Published
How to Cite
Issue
Section
